State Key Laboratory of Oncology in South China, Guangzhou, China; Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou.
Cancer. 2014 Mar 1;120(5):675-82. doi: 10.1002/cncr.28454. Epub 2013 Nov 5.
Several large studies have reported an extremely low incidence of MET gene amplification (GA) in patients with radically resected gastric cancer. This study was conducted to evaluate the prevalence and prognostic role of MET in patients with recurrent=metastatic gastric cancer who received chemotherapy.
MET GA and protein expression of recurrent=metastatic gastric cancer samples were evaluated by fluorescence in situ hybridization and immunohistochemistry (IHC), respectively.
This retrospective study included 232 patients with recurrent=metastatic gastric cancer. MET GA and strong protein expression(IHC31) were observed in 8.3% (19 of 230 samples) and 9.6% (22 of 229 samples) of samples, respectively. A significant correlation was observed between MET GA and protein expression (r = 0.378; P<.001). MET GA was correlated with poor performance status(P<.001) and poorly differentiated tumors (P=.0015). Both MET GA and IHC 31 expression were associated with a substantially shorter median overall survival (OS) and progression-free survival (PFS). The median OS and PFS for patients with MET GA versus those without MET GA were 5.7 months versus 15.5 months (P<.001) and 3.6 months versus 6.9 months (P<.001), respectively. The median OS and PFS for patients with MET IHC 31 expression versus IHC 0 to 21 expression were 6.3 months versus 15.1 months(P<.001) and 3.6 months versus 7.0 months (P<.001), respectively.
In patients with recurrent=metastatic gastric cancer,MET amplification and strong protein expression are not rare and appear to be significantly associated with unfavorable clinical outcomes.
几项大型研究报告称，根治性切除的胃癌患者中 MET 基因扩增（GA）的发生率极低。本研究旨在评估接受化疗的复发性转移性胃癌患者中 MET 的发生率和预后作用。
通过荧光原位杂交和免疫组织化学（IHC）分别评估复发性转移性胃癌样本中的 MET GA 和蛋白表达。
这项回顾性研究纳入了 232 例复发性转移性胃癌患者。在 230 例样本中有 8.3%（19 例）和 229 例样本中有 9.6%（22 例）观察到 MET GA 和强蛋白表达（IHC31）。MET GA 与蛋白表达之间存在显著相关性（r = 0.378；P<.001）。MET GA 与较差的表现状态（P<.001）和低分化肿瘤相关（P=.0015）。MET GA 和 IHC 31 表达均与中位总生存期（OS）和无进展生存期（PFS）显著缩短相关。与无 MET GA 的患者相比，有 MET GA 的患者中位 OS 和 PFS 分别为 5.7 个月和 15.5 个月（P<.001）和 3.6 个月和 6.9 个月（P<.001）。与 IHC 0 至 21 表达的患者相比，MET IHC 31 表达的患者中位 OS 和 PFS 分别为 6.3 个月和 15.1 个月（P<.001）和 3.6 个月和 7.0 个月（P<.001）。
在复发性转移性胃癌患者中，MET 扩增和强蛋白表达并不罕见，且与不良临床结局显著相关。
